KC
BMRN icon

Kepos Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kepos Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100,000
Closed -$8.23M – 229
2024
Q2 		$8.23M Hold
100,000
– – 3.2% 6
2024
Q1 		$8.73M Buy
+100,000
New +$8.95M 2.25% 11

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Kepos Capital's BMRN Position: Q3 2024 in Review

Kepos Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 100,000 shares — an estimated $8.23M sold.

Kepos Capital first reported a position in BMRN in Q1 2024 and held it in 2 quarters. The position peaked at $8.73M in Q1 2024. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

  • Kepos Capital reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Kepos Capital sold 100,000 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $8.23M.
  • Kepos Capital first reported a position in BioMarin Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Kepos Capital's BioMarin Pharmaceuticals position peaked at $8.73M in Q1 2024.
  • 553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Kepos Capital's 13F filing for Q3 2024, filed 12 Nov 2024.